MAR 24, 2019 07:39 PM PDT

Injectable Medicine Improves Genetic Rickets

WRITTEN BY: Nouran Amin

A recent study found that an injectable medicine called ‘Burosumab’ was shown to improve symptoms of X-linked hypophosphatemia (XLH)--an inherited form of rickets. According to the Food and Drug Administration (FDA), XLH affects roughly 3,000 children and 12,000 adults in the United States. Symptoms of XLH not only includes rickets, but also bowed legs, bone pain and short stature.

The study demonstrated that burosumab was successful in treating the XLH symptoms in comparison to conventional therapy which includes multiple daily doses of phosphate and vitamin D (e.g. calcitriol).

"These improvements with burosumab have the potential to change the lives of children with XLH as they grow," said study principal investigator Erik Imel, M.D., associate professor of medicine and pediatrics at Indiana University School of Medicine in Indianapolis, Ind.

Individuals with XLH have increased levels of the hormone fibroblast growth factor 23, or FGF23, which results in low blood levels of phosphorus (hypophosphatemia). In the study, patients were either assigned to continue on the conventional therapy or switch to receive the burosumab injections given every two weeks. Improvements were scored by X-rays that measured the degree of rickets along with improvements in in leg deformities, height and distance walked, and an increase in serum phosphorus and active vitamin D levels.

“By 40 weeks of treatment, that improvement was more than two times greater for the burosumab group than the conventional therapy group,” Imel noted. "We now know the magnitude of benefit from the new medication, burosumab, versus the prior approach with conventional therapy. This information is critical for doctors making treatment decisions for their patients with XLH."

Source: Medical Xpress

About the Author
  • Nouran enjoys writing on various topics including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
JAN 22, 2020
Drug Discovery & Development
JAN 22, 2020
Drug Seeks To Target Treatment-Resistant Epilepsy
Ever imagined a world where you cannot shower alone, drive by yourself, and even go to work in fear of having the next seizure that can incapacitate you? U...
JAN 22, 2020
Technology
JAN 22, 2020
How artificial intelligence (AI) is improving immunotherapy
Researchers at Case Western Reserve University’s digital imaging lab are pioneering the use of Artificial Intelligence (AI) to predict the efficacy o...
JAN 22, 2020
Health & Medicine
JAN 22, 2020
Once-a-Month Contraceptive Pill Closer to Reality
While a variety of contraceptive options exist, each has its pros and cons. As many women understand, one of the major drawbacks of the daily birth control...
JAN 22, 2020
Drug Discovery & Development
JAN 22, 2020
IV Treatment for Traumatic Brain Injury
Scientists are now using exosomes intravenously as a method of cell-to-cell technology for treating patients with traumatic brain injury (TBI). They discov...
JAN 22, 2020
Cell & Molecular Biology
JAN 22, 2020
An Antioxidant Found in Green Tea Can Fight Tuberculosis
In 2018, around ten million people around the globe were sickened by tuberculosis (TB) and about 1.5 million people were killed by tuberculosis....
JAN 22, 2020
Drug Discovery & Development
JAN 22, 2020
New Drug to Treat Migraines Approved by FDA
Over 1 in 10 people around the world- or 780 million people. Three times more common in women than in men, until now, most treatments have been preventativ...
Loading Comments...